GlassScriptPhysician profile
Bradee Burrell Aderholt
NPI 1508336173
$1,808.47
in general payments reported to CMS, 2019-2025
22 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $290 · 2022: $472 · 2023: $405 · 2024: $299 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $259.58 | 2021-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $200.22 | 2021-2024 | Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $195.11 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $172.08 | 2021-2025 | Jynarque |
| Vifor Pharma, INC. | $148.09 | 2021-2023 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $118.77 | 2022-2024 | Tarpeyo |
| Outset Medical INC | $109.54 | 2022 | |
| Horizon Therapeutics Plc | $108.24 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $105.37 | 2021-2023 | Lupkynis |
| Daiichi Sankyo INC. | $83.59 | 2021-2024 | Injectafer |
| Mallinckrodt Hospital Products INC. | $56.65 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $38.17 | 2021-2022 | |
| Travere Therapeutics, INC. | $33.62 | 2023 | |
| Glaxosmithkline, LLC. | $31.88 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $25.35 | 2024 | Libtayo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $24.98 | 2025 | Orenitram, Tyvaso, Remodulin |
| Ani Pharmaceuticals, INC. | $20.86 | 2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $18.06 | 2025 | Camzyos |
| Amgen INC. | $18.03 | 2022 | |
| Akebia Therapeutics INC | $17.28 | 2021 | |
| Lilly USA, LLC | $16.85 | 2024 | Jardiance |
| Cvrx, INC. | $6.15 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradee Aderholt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.